ClinicalTrials.gg
RecruitingNCT07774572Updated Aug 19, 2026

Exploration of Circular RNA in B-cell Hematologic Malignancies

A Phase 1 interventional study of Investigational product (IP) in Lymphoma, B-Cell Refractory, sponsored by Ruijin Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Ruijin Hospital · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Lymphoma by Ruijin Hospital — 12 open to participants now, 12 under way, none of them phase 3. Lymphoma · Ruijin Hospital.

Started
2026
the only one that year
Phase 1
Only one
of the 15
Primary completion
2027-03
later than 7 of 11 live
Registered
15th of 15
by date

Among the 15 studies in Lymphoma by Ruijin Hospital, this one is the only one that started in 2026, is the only one in phase 1, reaches primary completion later than 7 of the 11 other live ones, and was the 15th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

12 of the 15 studies in Lymphoma by Ruijin Hospital are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Lymphoma by Ruijin Hospital, or all of them as a file.
02

Study summary

This is an investigator-initiated, open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics (PD), and preliminary efficacy of an in vivo circular RNA chimeric antigen receptor T cell in adult participants with R/R B-cell malignancies.

Read the detailed description

This is an investigator-initiated, open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics (PD), and preliminary efficacy of an in vivo circular RNA chimeric antigen receptor T cell in adult participants with R/R B-cell malignancies.

Investigational product (IP)will be explored across four dose levels (as described in the table below) in adult participants with R/R B-cell malignancies, including diffuse large B-cell lymphoma [DLBCL], follicular lymphoma [FL], mantle cell lymphoma [MCL], chronic lymphocytic leukemia [CLL]/small lymphocytic lymphoma [SLL], Waldenström macroglobulinemia [WM], and marginal zone lymphoma (MZL).

The study consists of three periods: screening period, treatment period, and post-treatment follow-up period.

03

Conditions studied

  • Lymphoma, B-Cell Refractory

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years, any gender.
  2. Able to provide written .
  3. Confirmed diagnosis of (R/R) CD19-positive B-cell , including:

    • Diffuse large B-cell lymphoma (DLBCL)
    • Follicular lymphoma (FL)
    • Mantle cell lymphoma (MCL)
    • Small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL)
    • Waldenström macroglobulinemia (WM)
    • Marginal zone lymphoma (MZL)
  4. performance status 0 or 1.and have archival tumor tissue and pathology report from the most recent relapse, or at least one palpable superficial tumor lesion at screening, and agree to biopsy/resection before the first dose of IP for disease confirmation.
  5. Disease refractory to or relapsed after ≥ 2 prior lines of standard therapy, including required agents per disease subtype (e.g., anti-CD20, BTK inhibitors, chemotherapy, or if applicable).
  6. per Lugano 2014 or iwCLL 2018 criteria.
  7. ≥ 40% by echocardiogram.
  8. For patients with prior CD19-targeted therapy, confirmed CD19 positivity at screening.
  9. Women of (WOCBP) must have a negative serum pregnancy test and agree to use effective during the study and for 6 months after last treatment.
  10. Male patients with female partners must agree to use condoms, and partners must use effective contraception, during the study and for 6 months after last treatment.

Exclusion criteria

Exclusion Criteria:

  1. Prior anticancer therapy-related toxicities unresolved to baseline or ≤ Grade 1 (alopecia and peripheral neuropathy excepted).
  2. Central nervous system (CNS) involvement by lymphoma.
  3. Need for urgent treatment due to tumor mass effect or spinal cord compression.
  4. Known to any component of IP, including mRNA/LNP-based products.
  5. History of another primary within the past 3 years, except adequately treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ.
  6. Active (HBsAg-positive with detectable HBV DNA) or (HCV RNA-positive) infection.
  7. Active or prior infection.
  8. Uncontrolled active systemic infection requiring IV therapy within 1 week before dosing.
  9. Active or history of acute/chronic .
  10. Inadequate hematologic function (ANC \<1.0×10⁹/L, \<70 g/L, \<50×10⁹/L, lymphocytes ≤0.5×10⁹/L) or coagulation abnormalities (/APTT ≥1.5×).
  11. Hepatic impairment (/AST >2×ULN, or >3×ULN with hepatic involvement; >2×ULN, unless Gilbert syndrome).
  12. Renal impairment ( \<50 mL/min by Cockcroft-Gault).
  13. Uncontrolled ischemic heart disease, Class III-IV heart failure, or baseline ≥450 ms (male) / ≥470 ms (female).
  14. Severe psychiatric disorder history.
  15. Pregnancy or breastfeeding.
  16. Received prohibited treatments within 4 weeks before dosing, including high-dose (>20 mg prednisone equivalent daily), chemotherapy, therapy, prior CAR-T or other gene/cell therapy, or T-cell engagers.
  17. Participation in another clinical study with therapy within 3 months before dosing, or prior participation in cell/gene therapy trials.
  18. Planned radiotherapy within 6 weeks after screening (unless only non-irradiated PET-positive lesions remain eligible).
  19. Planned HSCT within 90 days after screening.
  20. Significant comorbidities or unstable medical conditions deemed by the investigator to compromise safety or study compliance.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Investigational product (IP)

    In Vivo Circular RNA Chimeric Antigen Receptor (CAR) T Cell Therapy

    Drug: Investigational product (IP)

Interventions

  • DrugInvestigational product (IP)

    In Vivo Circular RNA Chimeric Antigen Receptor (CAR) T Cell Therapy

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse events (TEAEs)

    Count the number and percentage of participants with treatment-emergent adverse events (TEAEs). The severity of all TEAEs is graded according to CTCAE Version 5.0.

    Time frame: From first dose of investigational product (IP) up to the end of study (Week 24 / EOS)

  2. Incidence of dose-limiting toxicities (DLTs)

    Count the number and percentage of participants who experience at least one dose-limiting toxicity (DLT) as defined by the study protocol.

    Time frame: 28 days after the first dose of IP

Secondary outcomes

  1. Overall Response Rate (ORR)

    Calculate the proportion of participants achieving Complete Response (CR) or Partial Response (PR). Tumor response is assessed per Lugano 2014 criteria, iWCLL 2018 criteria, and the 11th International WM Workshop criteria.

    Time frame: From Week 4 through Week 24 (EOS)

  2. Time to Response (TTR)

    Evaluate the time interval from the first IP infusion to the first documented CR or PR.

    Time frame: Up to Week 24 (EOS)

  3. Duration of Response (DOR)

    Evaluate the time interval from the first documented CR or PR to the first documented progressive disease (PD) or all-cause death, whichever occurs first.

    Time frame: Up to Week 48 survival follow-up

  4. Event-Free Survival (EFS)

    Evaluate the time interval from the first IP infusion to the first documented PD, relapse, initiation of new anti-lymphoma therapy, or all-cause death, whichever occurs first.

    Time frame: Up to Week 48 survival follow-up

  5. Progression-Free Survival (PFS)

    Evaluate the time interval from the first IP infusion to the first documented PD or all-cause death, whichever occurs first.

    Time frame: Up to Week 48 survival follow-up

  6. Absolute count and percentage of CAR-expressing positive immune cells

    Detect and analyze the absolute count and percentage of CAR-expressing positive immune cells in peripheral blood at each time point, and assess dynamic changes from baseline.

    Time frame: From pre-dose baseline through Week 24 (EOS)

  7. CD7 expression kinetics on immune cells

    Dynamically detect CD7 expression levels on peripheral blood immune cells at each time point and analyze kinetic changes from baseline.

    Time frame: From pre-dose baseline through Week 24 (EOS)

  8. Overall Survival (OS)

    Evaluate the time interval from the first IP infusion to all-cause death.

    Time frame: Up to Week 48 survival follow-up

  9. PK parameters of IP components

    Determine the PK parameters of the circRNA component and cationic lipid component of the IP respectively.

    Time frame: From pre-dose baseline through Week 24 (EOS)

  10. Incidence of immunogenicity to IP

    Count the number and percentage of participants with pre-existing antibodies (anti-PEG, anti-CAR, anti-CD7 VHH) and treatment-induced antibodies (anti-PEG, anti-CAR, anti-CD7 VHH) against IP.

    Time frame: From pre-dose baseline through Week 24 (EOS)

  11. Correlation between cytokine levels and treatment response adverse events(TRAE)

    Detect serum cytokine levels and conduct exploratory correlation analysis between cytokine concentrations and clinical outcomes.

    Time frame: From pre-dose baseline through Week 24 (EOS)

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Mar 2027, 10 months after the start.

Of 138 non-industry phase 1 interventional studies under Lymphoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 88. This study's planned 10 months is below that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
Aug 19, 2026
StartActual
May 26, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2029
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07774572
Lead sponsor
Ruijin Hospital
Collaborators
RiboX Therapeutics Ltd.
Responsible party
Sponsor
First posted
Aug 19, 2026
Start date
May 26, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2029 (estimated)
Last update
Aug 19, 2026

Study contacts

Li WANG
Contact
wl11194@rjh.com.cn
(+86)15062338287

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion